Bank of New York Mellon Corp Invests $188.72 Million in Waters Corporation $WAT

Key Points

• Bank of New York Mellon acquired 503,214 Waters shares worth approximately $188.7 million, giving it a 0.51% stake. Institutional investors collectively own 94.01% of the company.
• Waters reported quarterly EPS of $3.05, exceeding estimates of $3.01, while revenue reached $1.65 billion and rose 113.3% year over year.
• Analysts maintain a “Moderate Buy” consensus rating with an average price target of $420.35; the stock recently opened at $412.37, near its 52-week high of $421.74.

Bank of New York Mellon Corp bought a new position in Waters Corporation (NYSE:WAT - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 503,214 shares of the medical instruments supplier's stock, valued at approximately $188,725,000. Bank of New York Mellon Corp owned approximately 0.51% of Waters at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Avalon Trust Co bought a new stake in shares of Waters during the 2nd quarter valued at $499,000. SFE Investment Counsel bought a new position in Waters in the 2nd quarter worth $279,000. Everett Harris & Co. CA purchased a new stake in Waters in the 2nd quarter worth $11,248,000. Oppenheimer Asset Management Inc. purchased a new stake in Waters in the 2nd quarter worth $355,000. Finally, Bryn Mawr Trust Advisors LLC bought a new stake in Waters during the second quarter valued at about $2,351,000. Institutional investors own 94.01% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently commented on WAT. Morgan Stanley set a $430.00 price objective on Waters in a research report on Wednesday, August 5th. UBS Group increased their target price on Waters from $330.00 to $375.00 and gave the stock a "neutral" rating in a research report on Wednesday, May 6th. HSBC lifted their target price on Waters from $415.00 to $435.00 and gave the company a "buy" rating in a research note on Wednesday, June 3rd. Wall Street Zen cut Waters from a "buy" rating to a "hold" rating in a report on Monday, July 20th. Finally, Wolfe Research started coverage on Waters in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $425.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, Waters presently has a consensus rating of "Moderate Buy" and a consensus target price of $420.35.

Waters Stock Performance

Shares of NYSE:WAT opened at $412.37 on Friday. The firm has a fifty day simple moving average of $381.79 and a two-hundred day simple moving average of $347.24. Waters Corporation has a 52 week low of $282.77 and a 52 week high of $421.74. The company has a quick ratio of 1.29, a current ratio of 1.86 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $40.52 billion, a P/E ratio of 102.84, a PEG ratio of 2.39 and a beta of 1.19.

Waters (NYSE:WAT - Get Free Report) last announced its earnings results on Tuesday, August 4th. The medical instruments supplier reported $3.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.01 by $0.04. Waters had a net margin of 3.58% and a return on equity of 11.27%. The firm had revenue of $1.65 billion for the quarter, compared to analysts' expectations of $1.62 billion. During the same period in the prior year, the company earned $2.95 EPS. The business's revenue was up 113.3% compared to the same quarter last year. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. On average, analysts expect that Waters Corporation will post 14.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Waters news, Director Christopher A. Kuebler sold 3,626 shares of the business's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $397.94, for a total transaction of $1,442,930.44. Following the sale, the director directly owned 17,808 shares of the company's stock, valued at $7,086,515.52. The trade was a 16.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.31% of the stock is owned by insiders.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.

Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Corporation (NYSE:WAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source